PlumX Metrics
Embed PlumX Metrics

Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy

Journal of the National Cancer Institute, ISSN: 0027-8874, Vol: 105, Issue: 5, Page: 321-333
2013
  • 307
    Citations
  • 0
    Usage
  • 197
    Captures
  • 1
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

  • Citations
    307
  • Captures
    197
  • Mentions
    1
    • News Mentions
      1
      • News
        1

Most Recent News

Correlation of Histopathological and Radiological Response Patterns and Their Prognostic Implications in Breast Cancer After Neoadjuvant Chemotherapy

Introduction Neoadjuvant chemotherapy (NAC) has become the standard of care for breast cancer (BC) due to several key benefits. It facilitates breast-conserving surgery, potentially avoids

Article Description

Background: It has been proposed that magnetic resonance imaging (MRI) be used to guide breast cancer surgery by differentiating residual tumor from pathologic complete response (pCR) after neoadjuvant chemotherapy. This meta-analysis examines MRI accuracy in detecting residual tumor, investigates variables potentially affecting MRI performance, and compares MRI with other tests. Methods: A systematic literature search was undertaken. Hierarchical summary receiver operating characteristic (HSROC) models were used to estimate (relative) diagnostic odds ratios ([R]DORs). Summary sensitivity (correct identification of residual tumor), specificity (correct identification of pCR), and areas under the SROC curves (AUCs) were derived. All statistical tests were two-sided. Results: Forty-four studies (2050 patients) were included. The overall AUC of MRI was 0.88. Accuracy was lower for "standard" pCR definitions (referent category) than "less clearly described" (RDOR = 2.41, 95% confidence interval [CI] = 1.11 to 5.23) or "near-pCR" definitions (RDOR = 2.60, 95% CI = 0.73 to 9.24; P =. 03.) Corresponding AUCs were 0.83, 0.90, and 0.91. Specificity was higher when negative MRI was defined as contrast enhancement less than or equal to normal tissue (0.83, 95% CI = 0.64 to 0.93) vs no enhancement (0.54, 95% CI = 0.39 to 0.69; P =. 02), with comparable sensitivity (0.83, 95% CI = 0.69 to 0.91; vs 0.87, 95% CI = 0.80 to 0.92; P =. 45). MRI had higher accuracy than mammography (P =. 02); there was only weak evidence that MRI had higher accuracy than clinical examination (P =. 10). No difference in MRI and ultrasound accuracy was found (P =. 15). Conclusions: MRI accurately detects residual tumor after neoadjuvant chemotherapy. Accuracy was lower when pCR was more rigorously defined, and specificity was lower when test negativity thresholds were more stringent; these definitions require standardization. MRI is more accurate than mammography; however, studies comparing MRI and ultrasound are required. © The Author 2013. Published by Oxford University Press. All rights reserved.

Bibliographic Details

Marinovich, Michael L; Houssami, Nehmat; Macaskill, Petra; Sardanelli, Francesco; Irwig, Les; Mamounas, Eleftherios P; von Minckwitz, Gunter; Brennan, Meagan E; Ciatto, Stefano

Oxford University Press (OUP)

Medicine; Biochemistry, Genetics and Molecular Biology

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know